PŘEHLEDOVÉ ČLÁNKY Poruchy sekrécie rastového hormónu a ich vplyv na kostnú kvalitu | E19 / Vnitř Lék. 2024;70(5):E16-E20 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti: Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. Střet zájmů: Žádný. Financování: Ne. Registrace v databázích: Ne. Projednání etickou komisí: Ano. LITERATÚRA 1. Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. European journal of endocrinology / European Federation of Endocrine Societies. 2015;173(3):R131-51. 2. Hans D, Goertzen AL, Krieg MA, et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26(11):2762-9. 3. Briot K, Paternotte S, Kolta S, et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone. 2013;57(1):232-6. 4. Boutroy S, Hans D, Sornay-Rendu E, et al. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2013;24(1):77-85. 5. McCloskey EV, Oden A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX. J Bone Miner Res. 2016;31(5):940-8. 6. Rosen T, Wiren L, Wilhelmsen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. ClinEndocrinol(Oxf). 1994;40(1):111-6. 7. Arwert LI, Deijen JB, Muller M, et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. HormBehav. 2005;47(3):343-9. 8. Touskova V, Klouckova J, Durovcova V, et al. The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly. Physiological research. 2016;65(3):493-503. 9. Conway GS, Szarras-Czapnik M, et al. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood- -onset GH deficiency. EurJ Endocrinol. 2009;160(6):899-907. 10. Elbornsson M, Gotherstrom G, Franco C, et al. Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. EurJEndocrinol. 2012;166(2):181-9. 11. Rota F, Savanelli MC, Tauchmanova L, et al. Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J EndocrinolInvest. 2008;31(2):94-102. 12. Krantz E, Trimpou P, Landin-Wilhelmsen K. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study. J Clin Endocrinol Metab. 2015;100(9):3251-9. 13. Mo D, Fleseriu M, Qi R, Jia N, et al. Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 2015;3(5):331-8. 14. Appelman-Dijkstra NM, Claessen KM, Hamdy NA, et al. Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf). 2014;81(5):727-35. 15. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):852-60. 16. Amato G, Carella C, Fazio S, et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J ClinEndocrinolMetab. 1993;77(6):1671-6. 17. Degerblad M, Bengtsson BA, Bramnert M, et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. EurJ Endocrinol. 1995;133(2):180-8. 18. Jorgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth HormIGFRes. 2011;21(2):69-75. 19. Elbornsson M, Gotherstrom G, Bosaeus I, et al. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. EurJ Endocrinol. 2012;166(5):787-95. 20. Davidson P, Milne R, Chase D, et al. Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. ClinEndocrinol(Oxf). 2004;60(1):92-8. 21. Clanget C, Seck T, Hinke V, et al. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. ClinEndocrinol(Oxf). 2001;55(1):93-9. 22. Biermasz NR, Hamdy NA, Janssen YJ, et al. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J ClinEndocrinolMetab. 2001;86(7):3079-85. 23. Kuzma M, Kuzmova Z, Zelinkova Z, et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society. 2014;24(1):22-8. 24. Joseph F, Ahmad AM, Ul-Haq M, et al. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res. 2008;23(5):721-9. 25. Bereket A, Cesur Y, Ozkan B, et al. Circulating insulin-like growth factor binding protein-4 (IGFBP-4) is not regulated by parathyroid hormone and vitamin D in vivo: evidence from children with rickets. Journal of clinical research in pediatric endocrinology. 2010;2(1):17-20. 26. Soliman AT, Al Khalaf F, Alhemaidi N, et al. Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism. 2008;57(1):95-102. 27. Gomez JM, Maravall FJ, Gomez N, et al. Relationship between 25-(OH) D3, the IGF-I system, leptin, anthropometric and body composition variables in a healthy, randomly selected population. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2004;36(1):48-53. 28. Bogazzi F, Rossi G, Lombardi M, et al. Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. Journal of endocrinological investigation. 2011;34(8):e200-3. 29. Halupczok-Zyla J, Jawiarczyk-Przybylowska A, Bolanowski M. Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency. Frontiers in endocrinology. 2015;6:89. 30. Ameri P, Giusti A, Boschetti M, et al. Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. European journal of endocrinology / European Federation of Endocrine Societies. 2013;169(6):767-72. 31. Kuzma M, Binkley N, Bednarova A, et al. Trabecular Bone Score Change Differs with Regard to 25(Oh)D Levels in Patients Treated for Adult-Onset Growth Hormone Deficiency. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2016;22(8):951-8. 32. Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2004;15(2):155-9. 33. Riggs BL, Randall RV, Wahner HW, et al. The nature of the metabolic bone disorder in acromegaly. The Journal of clinical endocrinology and metabolism. 1972;34(6):911-8. 34. Kayath MJ, Vieira JG. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 1997;7(3):226-30. 35. Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2005;20(10):1837-44. 36. Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. The Journal of clinical endocrinology and metabolism. 2013;98(8):3402-10. 37. Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. The Journal of clinical endocrinology and metabolism. 2013;98(12):4808-15. 38. Ueland T, Bollerslev J, Godang K, et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. European journal of endocrinology. 2001;145(6):685-90. 39. Stepan J, Marek J, Havranek T, et al. Bone isoenzyme of serum alkaline phosphatase in acromegaly. Clinica chimica acta; international journal of clinical chemistry. 1979;93(3):355-63. 40. Scillitani A, Chiodini I, Carnevale V, et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1997;12(10):1729-36. 41. Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. The Journal of clinical endocrinology and metabolism. 2015;100(2):384-94. 42. Maffezzoni F, Maddalo M, Frara S, et al. High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine. 2016;54(2):532-42. 43. Malgo F, Hamdy NAT, Papapoulos SE, et al. Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture
RkJQdWJsaXNoZXIy NDA4Mjc=